ClinicalTrials.gov
public full text
Public Domain
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly#1030611
- Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.#1057592
- Octreotide in Treating Patients With Cancer-Related Malignant Ascites#803445
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly#876030
- Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly#1031085
Record · ID 836412
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive